289 related articles for article (PubMed ID: 8034340)
21. Protection against antigenically variable Borrelia burgdorferi conferred by recombinant vaccines.
Telford SR; Fikrig E; Barthold SW; Brunet LR; Spielman A; Flavell RA
J Exp Med; 1993 Aug; 178(2):755-8. PubMed ID: 8340764
[TBL] [Abstract][Full Text] [Related]
22. Oral vaccination with an attenuated Salmonella typhimurium strain expressing Borrelia burgdorferi OspA prevents murine Lyme borreliosis.
Dunne M; al-Ramadi BK; Barthold SW; Flavell RA; Fikrig E
Infect Immun; 1995 Apr; 63(4):1611-4. PubMed ID: 7890431
[TBL] [Abstract][Full Text] [Related]
23. An OspA-based DNA vaccine protects mice against infection with Borrelia burgdorferi.
Luke CJ; Carner K; Liang X; Barbour AG
J Infect Dis; 1997 Jan; 175(1):91-7. PubMed ID: 8985201
[TBL] [Abstract][Full Text] [Related]
24. Influence of outer surface protein A antibody on Borrelia burgdorferi within feeding ticks.
de Silva AM; Zeidner NS; Zhang Y; Dolan MC; Piesman J; Fikrig E
Infect Immun; 1999 Jan; 67(1):30-5. PubMed ID: 9864192
[TBL] [Abstract][Full Text] [Related]
25. Temporal changes in outer surface proteins A and C of the lyme disease-associated spirochete, Borrelia burgdorferi, during the chain of infection in ticks and mice.
Schwan TG; Piesman J
J Clin Microbiol; 2000 Jan; 38(1):382-8. PubMed ID: 10618120
[TBL] [Abstract][Full Text] [Related]
26. Demonstration of the ability of a canine Lyme vaccine to reduce the incidence of histological synovial lesions following experimentally-induced canine Lyme borreliosis.
Grosenbaugh DA; Rissi DR; Krimer PM
Vet Immunol Immunopathol; 2016 Nov; 180():29-33. PubMed ID: 27692092
[TBL] [Abstract][Full Text] [Related]
27. Immunization with a recombinant subunit OspA vaccine markedly impacts the rate of newly acquired Borrelia burgdorferi infections in client-owned dogs living in a coastal community in Maine, USA.
Eschner AK; Mugnai K
Parasit Vectors; 2015 Feb; 8():92. PubMed ID: 25890386
[TBL] [Abstract][Full Text] [Related]
28. Protective immunization with plasmid DNA containing the outer surface lipoprotein A gene of Borrelia burgdorferi is independent of an eukaryotic promoter.
Simon MM; Gern L; Hauser P; Zhong W; Nielsen PJ; Kramer MD; Brenner C; Wallich R
Eur J Immunol; 1996 Dec; 26(12):2831-40. PubMed ID: 8977275
[TBL] [Abstract][Full Text] [Related]
29. OspA antibodies inhibit the acquisition of Borrelia burgdorferi by Ixodes ticks.
de Silva AM; Fish D; Burkot TR; Zhang Y; Fikrig E
Infect Immun; 1997 Aug; 65(8):3146-50. PubMed ID: 9234767
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of a nonadjuvanted, outer surface protein A, recombinant vaccine in dogs after challenge by ticks naturally infected with Borrelia burgdorferi.
Conlon JA; Mather TN; Tanner P; Gallo G; Jacobson RH
Vet Ther; 2000; 1(2):96-107. PubMed ID: 19757556
[TBL] [Abstract][Full Text] [Related]
31. Vaccination against Lyme disease caused by diverse Borrelia burgdorferi.
Fikrig E; Telford SR; Wallich R; Chen M; Lobet Y; Matuschka FR; Kimsey RB; Kantor FS; Barthold SW; Spielman A; Flavell RA
J Exp Med; 1995 Jan; 181(1):215-21. PubMed ID: 7807004
[TBL] [Abstract][Full Text] [Related]
32. Differential efficacy of passive immunisation against infection by Lyme disease spirochaetes transmitted by partially fed vector ticks.
Shih CM; Liu LP
J Med Microbiol; 1998 Sep; 47(9):773-9. PubMed ID: 9736159
[TBL] [Abstract][Full Text] [Related]
33. Protection of dogs from Lyme disease with a vaccine containing outer surface protein (Osp) A, OspB, and the saponin adjuvant QS21.
Coughlin RT; Fish D; Mather TN; Ma J; Pavia C; Bulger P
J Infect Dis; 1995 Apr; 171(4):1049-52. PubMed ID: 7706788
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of human Lyme disease vaccine formulations in a mouse model.
Telford SR; Kantor FS; Lobet Y; Barthold SW; Spielman A; Flavell RA; Fikrig E
J Infect Dis; 1995 May; 171(5):1368-70. PubMed ID: 7751719
[TBL] [Abstract][Full Text] [Related]
35. Expression of outer surface proteins A and C of Borrelia burgdorferi in Ixodes ricinus ticks removed from humans.
Fingerle V; Liegl G; Munderloh U; Wilske B
Med Microbiol Immunol; 1998 Oct; 187(2):121-6. PubMed ID: 9832327
[TBL] [Abstract][Full Text] [Related]
36. Detection of multiple reactive protein species by immunoblotting after recombinant outer surface protein A lyme disease vaccination.
Molloy PJ; Berardi VP; Persing DH; Sigal LH
Clin Infect Dis; 2000 Jul; 31(1):42-7. PubMed ID: 10913394
[TBL] [Abstract][Full Text] [Related]
37. Design and development of a novel vaccine for protection against Lyme borreliosis.
Comstedt P; Hanner M; Schüler W; Meinke A; Lundberg U
PLoS One; 2014; 9(11):e113294. PubMed ID: 25409015
[TBL] [Abstract][Full Text] [Related]
38. Vaccination with meningococcal outer membrane vesicles carrying Borrelia OspA protects against experimental Lyme borreliosis.
Klouwens MJ; Salverda MLM; Trentelman JJ; Ersoz JI; Wagemakers A; Gerritzen MJH; van der Ley PA; Hovius JW
Vaccine; 2021 Apr; 39(18):2561-2567. PubMed ID: 33812741
[TBL] [Abstract][Full Text] [Related]
39. Temporal pattern of Borrelia burgdorferi p21 expression in ticks and the mammalian host.
Das S; Barthold SW; Giles SS; Montgomery RR; Telford SR; Fikrig E
J Clin Invest; 1997 Mar; 99(5):987-95. PubMed ID: 9062357
[TBL] [Abstract][Full Text] [Related]
40. Plasmid DNA and protein vaccination of mice to the outer surface protein A of Borrelia burgdorferi leads to induction of T helper cells with specificity for a major epitope and augmentation of protective IgG antibodies in vivo.
Zhong W; Wiesmüller KH; Kramer MD; Wallich R; Simon MM
Eur J Immunol; 1996 Nov; 26(11):2749-57. PubMed ID: 8921965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
